MedTrace Logo

Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity

NCT07701005 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 154

Last updated 2026-07-15

No results posted yet for this study

Summary

This single-center, retrospective observational cohort study evaluated early changes in non-invasive hepatic and metabolic indices (FIB-4, APRI, HSI, and the triglyceride-glucose \[TyG\] index) in adults with overweight or obesity who received once-weekly subcutaneous semaglutide or tirzepatide for metabolic risk reduction related to metabolic dysfunction-associated steatotic liver disease (MASLD). Baseline and follow-up (minimum 12 weeks) clinical, anthropometric, and laboratory data from 154 patients treated at a single tertiary-care center in Turkey were analyzed. The study assessed whether short-term incretin-based therapy was associated with changes in fibrosis-related indices (FIB-4, APRI) versus steatosis- and insulin resistance-related indices (HSI, TyG), and identified independent predictors of these changes using multivariable linear regression.

Conditions

Interventions

DRUG

Semaglutide

Once-weekly subcutaneous GLP-1 receptor agonist administered for at least 12 weeks; dose individualized and titrated at the treating physician's discretion according to routine clinical practice and patient tolerability.

DRUG

Tirzepatide

Once-weekly subcutaneous dual GIP/GLP-1 receptor agonist administered for at least 12 weeks; dose individualized and titrated at the treating physician's discretion according to routine clinical practice and patient tolerability.

Sponsors & Collaborators

  • Goztepe Prof Dr Suleyman Yalcın City Hospital

    lead OTHER

Principal Investigators

  • Ozgur Bahadir, MD · Istanbul Medeniyet University, Faculty of Medicine, Department of Gastroenterology

  • Ayse N Erbakan, MD,PhD · Istanbul Medeniyet University, Faculty of Medicine, Department of Internal Medicine

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2026-03-30
Completion
2026-04-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07701005 on ClinicalTrials.gov